Convenience Comparison Study of Reconstitution Devices for the Blood Coagulation Factor VIII Products Rurioctocog Alfa Pegol and Antihemophilic Factor (Recombinant)

Convenience Comparison Study of Reconstitution Devices for the Blood Coagulation Factor VIII Products Rurioctocog Alfa Pegol and Antihemophilic Factor (Recombinant)

Hitoshi Ueda,1 Misato Toyoda,1 Morio Arai,2 Michio Sakai3 1Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan; 2Takeda Development Center-Japan, Takeda Pharmaceutical Company Limited, Tokyo, Japan; 3Pediatrics Department, Munakata Suikokai General Hospital, Fukuoka, JapanCorre...

Full description

Bibliographic Details
Main Authors:	Ueda H, Toyoda M, Arai M, Sakai M
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-12-01
Series:	International Journal of General Medicine
Subjects:	coagulation factor viii product reconstitution device crossover comparison study hemophilia treatment usability
Online Access:	https://www.dovepress.com/convenience-comparison-study-of-reconstitution-devices-for-the-blood-c-peer-reviewed-article-IJGM

Similar Items

Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Safety
by: Reinhard Stidl, et al.
Published: (2018-07-01)

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
by: Napolitano M, et al.
Published: (2021-01-01)

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
by: Lieuw K
Published: (2017-06-01)

Giant Intramural Hematoma of the Colon in Acquired Factor VIII Inhibitor
by: Joana Figueiredo, et al.
Published: (2019-09-01)

Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro
by: Masahiro Takeyama, et al.
Published: (2020-10-01)

Endothelial cell synthesis of Factor VIII
by: Riches, Jonathan Jacob
Published: (2013)

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII
by: Jenni Firrman, et al.
Published: (2020-06-01)

Acquired factor VIII inhibitor associated with chronic untreated hepatitis C
by: Abdussalam Shredi, et al.
Published: (2018-04-01)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies
by: David W. Scott, et al.
Published: (2020-01-01)

Repression of factor VIII inhibitor development with apoptotic factor VIII-expressing embryonic stem cells
by: Yoshihiko Sakurai, et al.
Published: (2013-07-01)

Acquired factor VIII inhibitor syndrome: A rare cause of hematuria
by: Muthuvel Seral Kannan, et al.
Published: (2015-01-01)

Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
by: Zhen-Ping Chen, et al.
Published: (2018-01-01)

Desenvolvimento de inibidores do fator VIII na hemofilia A Development of factor VIII inhibitors in hemophilia A
by: Daniel G. Chaves, et al.
Published: (2009-01-01)

Factor VIII products: key aspects of development, clinical research and use (part 1)
by: Zh. I. Avdeeva, et al.
Published: (2021-03-01)

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy
by: Alex C. Chen, et al.
Published: (2020-04-01)

The prevalence of factor VIII inhibitor in patients with severe hemophilia-A and its clinical characteristics
by: Harijadi Harijadi, et al.
Published: (2016-10-01)

Structural and functional aspects of factor viii in the initiation of the anti-factor viii immune response
by: Gangadharan, Bagirath
Published: (2014)

Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII
by: Philip M. Zakas, et al.
Published: (2020-02-01)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
by: Wynn TT, et al.
Published: (2016-06-01)

Identification of plasma antibody epitopes and gene abnormalities in Japanese hemophilia a patients with factor VIII inhibitor
by: Sugihara, Takuro, et al.
Published: (2000)

Murine leukemia virus-derived retroviral vector has differential integration patterns in human cell lines used to produce recombinant factor VIII
by: Marcela Cristina Correa de Freitas, et al.
Published: (2014-06-01)

CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY
by: Saima Zahir, et al.
Published: (2021-02-01)

Recently approved recombinant factor VIII (rFVIII) for the replacement treatment in patients with hemophilia A in Italy
by: Daniela Paola Roggeri, et al.
Published: (2017-10-01)

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
by: Di Minno G, et al.
Published: (2019-01-01)

Obtenção e caracterização de anticorpo monoclonal murino anti-fator VIII da coagulação sangüínea Attainment and characterization of murine monoclonal anti-factor VIII antibodies
by: Rosana Rossi-Ferreira, et al.
Published: (2006-06-01)

Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion
by: Jeong Pil Han, et al.
Published: (2021-07-01)

Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?
by: Laila M. Sherief, et al.
Published: (2020-09-01)

The Effect of 8-Weeks Exercise in Water on Factor VIII and Partial Thromboplastin Time (PTT) of Men with Hemophilia
by: Marziyeh Soltani, et al.
Published: (2016-01-01)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
by: Jerome Teitel, et al.
Published: (2021-02-01)

Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
by: Chun-Yu Chen, et al.
Published: (2020-06-01)

Tolerating Factor VIII: Recent Progress
by: Sebastien Lacroix-Desmazes, et al.
Published: (2020-01-01)

Factor VIII-Intron 1 Inversion of Hemophilia A Patients In West Anatolia
by: Pehlivan M, et al.
Published: (2007-04-01)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
by: Alexandra Sherman, et al.
Published: (2017-11-01)

Critical Review of the Pivotal Studies of Four rFVIII Products for the Treatment of Hemophilia A Patients: The Role of Octocog Alfa
by: Matteo Nicola Dario Di Minno, et al.
Published: (2020-04-01)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
by: Byung Suk Moon, et al.
Published: (2013-07-01)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
by: Pratima Chowdary, et al.
Published: (2019-07-01)

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis
by: Alanna McEneny-King, et al.
Published: (2017-10-01)

Comparative analysis of chromogenic vs clot.based one stage APTT assay for determination of factor VIII level
by: Mirza Asif Baig, et al.
Published: (2021-01-01)

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits
by: Mario Schiavoni, et al.
Published: (2019-12-01)

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report
by: Beth Boulden Warren, et al.
Published: (2021-07-01)